Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Hyderabad, Biological E. Ltd, a Hyderabad-based vaccine and <keyword id="24214" type="COMPANY" weightage="20" keywordseo="pharmaceutical-company">pharmaceutical company</keyword>, and <keyword id="10398356" type="COMPANY" weightage="20" keywordseo="the-ohio-state-innovation-foundation">the Ohio State Innovation Foundation</keyword> on Tuesday announced an exclusive license agreement for a Covid-19 vaccine technology. The <keyword id="15091" type="LOCATION" weightage="20" keywordseo="Ohio">Ohio</keyword> State Innovation Foundation has licensed novel live attenuated measles virus vectored vaccine candidates against SARS-CoV-2, which were developed by the <keyword id="10398357" type="UNKNOWN" weightage="20" keywordseo="ohio-state-university-college">Ohio State University College</keyword> of Veterinary Medicine, exclusively to Biological E. BE will be responsible for the evaluation and further development, including the commercialisation of the vaccine candidates. "Translating this vaccine platform into the hands of a global vaccine company for further evaluation and development is a critical step and we are excited that Biological E has taken on this role," said Dr Patrick Green, Associate Dean for Research and Graduate Studies, <keyword id="123150" type="COMPANY" weightage="20" keywordseo="Ohio-State-University">Ohio State University</keyword> College of Veterinary Medicine. The Ohio college team's approach utilises the SARS-CoV-2 spike protein as a target protein for SARS-CoV-2 vaccine candidates, generating a series of attenuated recombinant measles viruses (rMeVs) expressing SARS-CoV-2 antigens. All resultant rMeVs, the basis for the vaccine candidates, grow to high virus titer in Vero cells, a WHO-approved cell line for vaccine production. They were also shown to express the recombinant S antigens, a critical step in developing a SARS-CoV-2 vaccine. The rMeV-based SARs-CoV-2 vaccine candidates have proceeded through proof-of-concept trials in multiple animal models - demonstrating successful production of SARS-CoV-2 antibodies. "BE has been working to develop a safe and effective vaccine for the COVID-19. BE is very happy to help further this innovation and expand that effort," said Mahima Datla, Managing Director, Biological E. "With this licensing transaction, we have expanded the repertoire of the candidate vaccine(s) that we are evaluating, both in terms of the antigen and the platform technology," said Narender Dev Mantena, Director, BioE Holdings Inc., who heads BE's novel vaccine initiative. SEE ALSO: <a href="https://www.businessinsider.in/business/telecom/news/mukesh-ambani-says-jio-will-rollout-5g-services-by-june-2021-and-it-will-go-beyond-india/articleshow/79619222.cms">Mukesh Ambani says Jio will rollout 5G services by June 2021 – and it will go beyond India</a> <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-canara-bank-sun-pharma-titan-nbcc-gujarat-state-fertilizers-coffee-day-and-others/articleshow/79617464.cms">Top stocks to watch — Canara Bank, Sun Pharma, Titan, NBCC, Gujarat State Fertilizers, Coffee Day, and others</a>

You Searched For "BioE Holdings Inc" and got 1 results

Biological E gets license for Ohio varsity's COVID-19 vaccine technology

IANS

Popular Keywords

Buying Guides